ReviewPharmaceutics2023
Combination Therapy as a Promising Way to Fight Oral Cancer.
Review in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 42 citations in OpenAlex.
- In-silico and In-vitro Gene Expression Analysis on Docetaxel and Methotrexate-induced Cytotoxicity in Oral Cancer Cell Line.Cell biochemistry and biophysics · 2026Article
- Preparation of FeInternational journal of nanomedicine · 2026Article
- Molecular Docking and Single-Cell RNA-Seq Analysis IdentifyCurrent medicinal chemistry · 2026Article
- Commentary on "Targeting protein kinase D in oral squamous cell carcinoma: a promising therapeutic approach" by Dandapani.International journal of surgery (London, England) · 2026Article
- Cellular Senescence as a Risk Factor in Head and Neck Cancer-Diagnostic and Therapeutic Perspective.Cancers · 2025Review
- Synergistic potential of Ivermectin and doxorubicin in oral squamous cell carcinoma: an in vitro investigation.BMC pharmacology & toxicology · 2025Article
- Research progress on carcinogenic factors and personalized treatment of oral cancer.Discover oncology · 2025Review
- Roles of Wnt ligands and receptors in oral squamous cell carcinoma.Journal of Zhejiang University. Science. B · 2025Review
- Review
- Review
- The Src family kinase inhibitor drug Dasatinib and glucocorticoids display synergistic activity against tongue squamous cell carcinoma and reduce MET kinase activity.Cell communication and signaling : CCS · 2025Article
- Development of TheranosticACS applied bio materials · 2025Article
- Oral squamous cell carcinoma: Insights into cellular heterogeneity, drug resistance, and evolutionary trajectories.Cell biology and toxicology · 2025Review
- A bibliometric analysis of programmed cell death in oral cancer literature: research patterns and emerging trends (2000-2024).Discover oncology · 2025Article
- Exploring cell death pathways in oral cancer: mechanisms, therapeutic strategies, and future perspectives.Discover oncology · 2025Review
- Profiling genetic mutations in the DNA damage repair genes of oral squamous cell carcinoma patients from Pakistan.Scientific reports · 2025Article
- Cutting-Edge Advances in Anticancer Therapies: Insights from the Third Edition of the Special Issue "Novel Anticancer Strategies".Pharmaceutics · 2025Article
- Unravelling molecular mechanism of oral squamous cell carcinoma and genetic landscape: an insight into disease complexity, available therapies, and future considerations.Frontiers in immunology · 2025Review
- Advances in Preventive and Therapeutic Strategies for Oral Cancer: A Short Review.Journal of cancer prevention · 2024Review
- Enhanced anti-glioma activity of annonaceous acetogenins based on a novel liposomal co-delivery system with ginsenoside Rh2.Drug delivery · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Oral cancer is a highly aggressive tumor with invasive properties that can lead to metastasis and high mortality rates. Conventional treatment strategies, such as surgery, chemotherapy, and radiation therapy, alone or in combination, are associated with significant side effects. Currently, combination therapy has become the standard practice for the treatment of locally advanced oral cancer, emerging as an effective approach in improving outcomes. In this review, we present an in-depth analysis of the current advancements in combination therapies for oral cancer. The review explores the current therapeutic options and highlights the limitations of monotherapy approaches. It then focuses on combinatorial approaches that target microtubules, as well as various signaling pathway components implicated in oral cancer progression, namely, DNA repair players, the epidermal growth factor receptor, cyclin-dependent kinases, epigenetic readers, and immune checkpoint proteins. The review discusses the rationale behind combining different agents and examines the preclinical and clinical evidence supporting the effectiveness of these combinations, emphasizing their ability to enhance treatment response and overcome drug resistance. Challenges and limitations associated with combination therapy are discussed, including potential toxicity and the need for personalized treatment approaches. A future perspective is also provided to highlight the existing challenges and possible resolutions toward the clinical translation of current oral cancer therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.